Revelation Biosciences (REVB) Common Equity (2020 - 2026)
Revelation Biosciences (REVB) posted quarterly Common Equity of $8.9 million for Q4 2025, up 89.02% year-over-year from $4.7 million in Q4 2024, and down 19.09% quarter-over-quarter from $11.0 million in Q3 2025.
Revelation Biosciences (REVB) Common Equity (2020 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Common Equity for 6 consecutive years, with $8.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity rose 89.02% year-over-year to $8.9 million; the TTM figure through Dec 2025 stood at $8.9 million (up 89.02% YoY), while the FY2025 annual figure was $8.9 million, up 89.02% from the prior year.
- Common Equity declined to $8.9 million in Q4 2025 per REVB's latest filing, from $11.0 million in the prior quarter.
- Across five years, Common Equity topped out at $11.4 million in Q2 2023 and bottomed at -$1.8 million in Q2 2022.
- Historically, Common Equity has averaged $5.1 million across 5 years, with a median of $4.3 million in 2024.
- Annual changes were most pronounced in 2021 — Common Equity soared 48404.85% — and 2022, when it slumped 128.06%.
- Revelation Biosciences' Common Equity stood at -$99470.0 in 2021, then jumped by 1158.06% to $1.1 million in 2022, then surged by 531.64% to $6.6 million in 2023, then fell by 29.17% to $4.7 million in 2024, then jumped by 89.02% to $8.9 million in 2025.
- Business Quant data shows REVB's Common Equity at $8.9 million in Q4 2025, $11.0 million in Q3 2025, and $3.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | 10.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.10 Mn |
| Dec 31, 2025 | 8.90 Mn |
| Sep 30, 2025 | 11.00 Mn |
| Jun 30, 2025 | 3.83 Mn |
| Mar 31, 2025 | 2.88 Mn |
| Dec 31, 2024 | 4.71 Mn |
| Sep 30, 2024 | 2.67 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 9.47 Mn |
| Dec 31, 2023 | 6.65 Mn |
| Sep 30, 2023 | 8.82 Mn |
| Jun 30, 2023 | 11.41 Mn |
| Mar 31, 2023 | 10.02 Mn |
| Dec 31, 2022 | 1.05 Mn |
| Sep 30, 2022 | 2.23 Mn |
| Jun 30, 2022 | -1.84 Mn |
| Mar 31, 2022 | -98,511.00 |
| Dec 31, 2021 | -99,470.00 |
| Sep 30, 2021 | 3.66 Mn |
| Jun 30, 2021 | 6.57 Mn |